Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson’s disease
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson’s disease
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 24, Issue 2, Pages 219-227
Publisher
Informa Healthcare
Online
2014-09-17
DOI
10.1517/13543784.2015.963195
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease
- (2015) Iciar Aviles-Olmos et al. Journal of Parkinsons Disease
- Does Parkinson’s Disease and Type-2 Diabetes Mellitus Present Common Pathophysiological Mechanisms and Treatments?
- (2014) Marcelo Lima et al. CNS & Neurological Disorders-Drug Targets
- Molecular Effects of L-dopa Therapy in Parkinson’s Disease
- (2014) Jolanta Dorszewska et al. CURRENT GENOMICS
- Levodopa-related cysteinyl–glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson’s disease patients
- (2014) Thomas Müller et al. JOURNAL OF NEURAL TRANSMISSION
- Expression of peroxisome proliferator-activated receptor-gamma in the substantia nigra of hemiparkinsonian nonhuman primates
- (2014) Christine Swanson et al. NEUROLOGICAL RESEARCH
- Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials
- (2013) Matteo Monami et al. ACTA DIABETOLOGICA
- Comparing Pioglitazone to Insulin with Respect to Cancer, Cardiovascular and Bone Fracture Endpoints, Using Propensity Score Weights
- (2013) Carlos Vallarino et al. CLINICAL DRUG INVESTIGATION
- Methyl Group–Donating Vitamins Elevate 3-O-Methyldopa in Patients With Parkinson Disease
- (2013) Thomas Müller et al. CLINICAL NEUROPHARMACOLOGY
- PPAR-γ: Therapeutic Prospects in Parkinson's Disease
- (2013) Anna R. Carta CURRENT DRUG TARGETS
- Pioglitazone and Cancer: Angel or Demon?
- (2013) Michael Kostapanos et al. CURRENT PHARMACEUTICAL DESIGN
- Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies
- (2013) M. Ferwana et al. DIABETIC MEDICINE
- Exenatide and the treatment of patients with Parkinson’s disease
- (2013) Iciar Aviles-Olmos et al. JOURNAL OF CLINICAL INVESTIGATION
- Peroxisome Proliferator-Activated Receptor Agonists and Bladder Cancer: Lessons from Animal Studies
- (2013) CHIN-HSIAO TSENG et al. JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART C-ENVIRONMENTAL CARCINOGENESIS & ECOTOXICOLOGY REVIEWS
- Sleep and non-motor symptoms in Parkinson’s disease
- (2013) Antonia Maass et al. JOURNAL OF NEURAL TRANSMISSION
- Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease
- (2013) Bradley F Boeve LANCET NEUROLOGY
- Obstacles to the Development of a Neuroprotective Therapy for Parkinson's Disease
- (2013) Fabrizio Stocchi et al. MOVEMENT DISORDERS
- Cancer Risk for Patients Using Thiazolidinediones for Type 2 Diabetes: A Meta-Analysis
- (2013) C. Bosetti et al. ONCOLOGIST
- Shared dysregulated pathways lead to Parkinson's disease and diabetes
- (2013) Jose A. Santiago et al. TRENDS IN MOLECULAR MEDICINE
- Neuroprotective Properties of a Novel Non-Thiazoledinedione Partial PPAR-γAgonist against MPTP
- (2013) Christine R. Swanson et al. PPAR Research
- Parkinson's disease, insulin resistance and novel agents of neuroprotection
- (2012) Iciar Aviles-Olmos et al. BRAIN
- Pioglitazone and bladder cancer: a propensity score matched cohort study
- (2012) Li Wei et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis
- (2012) I. N. Colmers et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: A meta-analysis
- (2012) Zhaowei Zhu et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study
- (2012) A. Neumann et al. DIABETOLOGIA
- Association Between Longer Therapy With Thiazolidinediones and Risk of Bladder Cancer: A Cohort Study
- (2012) Ronac Mamtani et al. JNCI-Journal of the National Cancer Institute
- Clinical features of Parkinson disease when onset of diabetes came first: A case-control study
- (2012) E. Cereda et al. NEUROLOGY
- Association Between Pioglitazone and Urothelial Bladder Cancer
- (2012) Yanina Barbalat et al. UROLOGY
- The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study
- (2012) L. Azoulay et al. BMJ-British Medical Journal
- PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation
- (2011) Tamas Varga et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- PARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease
- (2011) Joo-Ho Shin et al. CELL
- Pioglitazone and Bladder Cancer: A population-based study of Taiwanese
- (2011) C.-H. Tseng DIABETES CARE
- Diabetes and Risk of Parkinson's Disease
- (2011) Q. Xu et al. DIABETES CARE
- Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone: Interim report of a longitudinal cohort study
- (2011) J. D. Lewis et al. DIABETES CARE
- The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys
- (2011) Christine R Swanson et al. Journal of Neuroinflammation
- Cysteinyl-glycine reduction as marker for levodopa-induced oxidative stress in Parkinson's disease patients
- (2011) Thomas Müller et al. MOVEMENT DISORDERS
- Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts
- (2011) Kurt A. Jellinger MOVEMENT DISORDERS
- The controversy of levodopa toxicity in Parkinson disease
- (2011) Theresa A. Zesiewicz Nature Reviews Neurology
- Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model
- (2011) A.R. Carta et al. NEUROSCIENCE
- PGC-1 , A Potential Therapeutic Target for Early Intervention in Parkinson's Disease
- (2010) B. Zheng et al. Science Translational Medicine
- Unbalanced M1/M2 Phenotype of Peripheral Blood Monocytes in Obese Diabetic Patients: Effect of pioglitazone
- (2009) N. Satoh et al. DIABETES CARE
- PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson’s disease
- (2009) Nicoletta Schintu et al. EUROPEAN JOURNAL OF NEUROSCIENCE
- Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
- (2009) Philip D Home et al. LANCET
- A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
- (2009) C. Warren Olanow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Pioglitazone, a Peroxisome Proliferator–Activated Receptor Gamma Agonist, on the Urine and Urothelium of the Rat
- (2009) Shugo Suzuki et al. TOXICOLOGICAL SCIENCES
- Beneficial effects of pioglitazone on cognitive impairment in MPTP model of Parkinson's disease
- (2008) Pramod Kumar et al. BEHAVIOURAL BRAIN RESEARCH
- Rosiglitazone-Associated Fractures in Type 2 Diabetes: An analysis from A Diabetes Outcome Progression Trial (ADOPT)
- (2008) S. E. Kahn et al. DIABETES CARE
- Expression of Peroxisome Proliferator-Activated Receptor-γ in Key Neuronal Subsets Regulating Glucose Metabolism and Energy Homeostasis
- (2008) David A. Sarruf et al. ENDOCRINOLOGY
- PPAR: a therapeutic target in Parkinsons disease
- (2008) Rajnish K. Chaturvedi et al. JOURNAL OF NEUROCHEMISTRY
- Complete Rescue of Cerebrovascular Function in Aged Alzheimer's Disease Transgenic Mice by Antioxidants and Pioglitazone, a Peroxisome Proliferator-Activated Receptor Agonist
- (2008) N. Nicolakakis et al. JOURNAL OF NEUROSCIENCE
- The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease
- (2008) Anthony H.V. Schapira MOVEMENT DISORDERS
- Regulation of Glial Cell Functions by PPAR- Natural and Synthetic Agonists
- (2008) Antonietta Bernardo et al. PPAR Research
- Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists
- (2007) Ramya Kapadia Frontiers in Bioscience-Landmark
- Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague–Dawley rats
- (2007) Randy L. Hunter et al. NEUROSCIENCE LETTERS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now